Xencor (NASDAQ:XNCR) Sees Strong Trading Volume

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 437,532 shares traded hands during trading, a decline of 36% from the previous session's volume of 680,063 shares.The stock last traded at $22.45 and had previously closed at $20.94.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on XNCR shares. BMO Capital Markets dropped their price target on shares of Xencor from $38.00 to $34.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 28th. StockNews.com raised shares of Xencor from a "sell" rating to a "hold" rating in a research note on Saturday, March 9th. Mizuho dropped their price target on shares of Xencor from $59.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, January 22nd. Wedbush dropped their price target on shares of Xencor from $36.00 to $34.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 28th. Finally, BTIG Research dropped their target price on shares of Xencor from $56.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.00.

Xencor Trading Up 14.3 %

The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 0.02. The business's 50-day moving average is $21.91 and its two-hundred day moving average is $20.39. The firm has a market cap of $1.48 billion, a P/E ratio of -10.87 and a beta of 0.76.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.36 by ($0.67). The firm had revenue of $44.70 million for the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The company's revenue for the quarter was up 106.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.20) earnings per share. As a group, analysts expect that Xencor, Inc. will post -3.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Xencor

In other Xencor news, VP John R. Desjarlais sold 1,280 shares of the business's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $23.50, for a total transaction of $30,080.00. Following the completion of the transaction, the vice president now directly owns 186,433 shares of the company's stock, valued at approximately $4,381,175.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Bassil I. Dahiyat sold 2,741 shares of the company's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $23.50, for a total value of $64,413.50. Following the completion of the sale, the chief executive officer now directly owns 351,894 shares of the company's stock, valued at approximately $8,269,509. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP John R. Desjarlais sold 1,280 shares of the company's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $30,080.00. Following the completion of the sale, the vice president now directly owns 186,433 shares of the company's stock, valued at $4,381,175.50. The disclosure for this sale can be found here. Insiders sold 101,351 shares of company stock valued at $2,152,417 in the last ninety days. Company insiders own 4.97% of the company's stock.

Institutional Trading of Xencor

A number of institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC raised its holdings in shares of Xencor by 303.9% in the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 1,015 shares in the last quarter. CWM LLC raised its holdings in shares of Xencor by 498.7% in the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 1,147 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Xencor by 367.7% in the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,151 shares in the last quarter. BluePath Capital Management LLC bought a new stake in shares of Xencor in the 3rd quarter worth approximately $31,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Xencor by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 756 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.